[SCHEDULE 13G] CS DIAGNOSTICS CORP. SEC Filing
Thomas Graus filed a Schedule 13G reporting beneficial ownership of 13,392,434 shares of CS Diagnostics Corp. common stock, equal to
Thomas Graus ha depositato una Schedule 13G che riporta la proprietà beneficiaria di 13.392.434 azioni ordinarie di CS Diagnostics Corp., pari a
Thomas Graus presentó un Schedule 13G que reporta la propiedad beneficiaria de 13,392,434 acciones ordinarias de CS Diagnostics Corp., equivalente a
Thomas Graus는 CS Diagnostics Corp. 일반 주식의 수혜 귀속을 보고하는 Schedule 13G를 제출했으며, 보유 주식 수는 13,392,434주로서 당 시의
Thomas Graus a déposé un Schedule 13G indiquant la propriété bénéficiaire de 13,392,434 actions ordinaires de CS Diagnostics Corp., soit
Thomas Graus hat ein Schedule 13G eingereicht, das die wirtschaftlich Berechtigten an 13.392.434 Stammaktien der CS Diagnostics Corp. meldet, was
Thomas Graus قد قدّم Schedule 13G يُبلغ عن الملكية المستفيدة لــ 13,392,434 أسهم عادية من CS Diagnostics Corp.، مساوية لـ
Thomas Graus 提交了 Schedule 13G,报告 CS Diagnostics Corp.普通股的实际拥有情况,共 13,392,434 股,约占公司类别的
- None.
- None.
Insights
Insider holds a near‑cap position: 13.39M shares (9.9%).
The reported stake is a mix of direct common stock and convertible Series B preferred shares, with conversion limited to avoid exceeding
Key dependencies include the Certificate of Designation cap and the outstanding share count used to compute the
Control implications are limited despite large economic stake.
The filing notes that Preferred A shares carry supervoting rights that concentrate >90% of voting power with their holder, and therefore the reported holder does not claim de facto control. This distinguishes economic ownership from control and affects corporate governance dynamics.
Investors should note the certification that the position was not acquired to influence control and monitor any future amendments, Schedule 13D filings, or changes to voting structures that could indicate a shift from passive to active intent within a
Thomas Graus ha depositato una Schedule 13G che riporta la proprietà beneficiaria di 13.392.434 azioni ordinarie di CS Diagnostics Corp., pari a
Thomas Graus presentó un Schedule 13G que reporta la propiedad beneficiaria de 13,392,434 acciones ordinarias de CS Diagnostics Corp., equivalente a
Thomas Graus는 CS Diagnostics Corp. 일반 주식의 수혜 귀속을 보고하는 Schedule 13G를 제출했으며, 보유 주식 수는 13,392,434주로서 당 시의
Thomas Graus a déposé un Schedule 13G indiquant la propriété bénéficiaire de 13,392,434 actions ordinaires de CS Diagnostics Corp., soit
Thomas Graus hat ein Schedule 13G eingereicht, das die wirtschaftlich Berechtigten an 13.392.434 Stammaktien der CS Diagnostics Corp. meldet, was